The CCL2-CCR2 signaling axis association with aggressive tumor progression has been reported in inflammatory breast cancers and pancreatic cancers and demonstrated in the B16F10 model of advanced melanoma. This evidence concerns the gene CCL2 and pancreatic neoplasm.